Product image of Orfiril Saft (Sodium Valproate) supplied by GNH India

Orfiril Saft

Active Ingredient:
Sodium Valproate
Origin:
EU

Orfiril Saft (Sodium Valproate)

Sodium Valproate, the active ingredient in Orfiril Saft, is an anticonvulsant presented as an oral solution for oral use. It treats epilepsy and related seizure disorders in children and adults.\n\nGNH India supplies Orfiril Saft as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Desitin Arzneimittel Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Orfiril Saft, a sodium valproate formulation, is used across several seizure‑related conditions and mood disorders.\n\n- Generalized tonic‑clonic seizures: reduces seizure frequency and severity.\n- Absence seizures: helps achieve seizure control in typical absence epilepsy.\n- Myoclonic seizures: diminishes myoclonic jerks and improves daily function.\n- Lennox‑Gastaut syndrome: lowers the number of drop attacks and improves quality of life.\n- Bipolar disorder (mood stabilization): assists in preventing manic episodes when prescribed by a psychiatrist.

How It Works

  • Sodium valproate enhances gamma‑aminobutyric acid (GABA) concentrations by inhibiting its degradation, while also blocking voltage‑gated sodium channels and T‑type calcium channels. These actions stabilize neuronal membranes and suppress abnormal hyper‑excitability, thereby reducing the likelihood of seizure propagation and providing mood‑stabilising effects.

Side Effects

  • Adverse reactions may occur with sodium valproate therapy and vary in frequency and severity.\n\nCommon Side Effects:\n- Nausea and vomiting\n- Weight gain\n- Tremor\n- Drowsiness or fatigue\n- Hair thinning or loss\n\nSerious or Rare Side Effects:\n- Hepatotoxicity (liver injury)\n- Acute pancreatitis\n- Thrombocytopenia or other blood dyscrasias\n- Severe skin reactions such as Stevens‑Johnson syndrome\n- Hyperammonemic encephalopathy\n- Fatal overdose in overdose situations.

Precautions & Warnings

  • When prescribing Orfiril Saft, clinicians should observe several safety measures.\n\n- Liver monitoring: assess hepatic enzymes before initiation and periodically during therapy.\n- Blood count monitoring: check platelet levels and complete blood count regularly.\n- Pregnancy caution: avoid use in pregnancy unless benefits outweigh risks, due to teratogenic potential.\n- Mitochondrial disorder warning: contraindicated in patients with known mitochondrial disease.\n- Dose adjustment: consider reduced dosing in hepatic or renal impairment.\n- Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

  • Sodium valproate may interact with several medicines, altering efficacy or safety.\n\nMajor Interactions (Avoid):\n- Carbamazepine: induces metabolism, lowering valproate plasma levels.\n- Phenobarbital: reduces valproate concentrations through hepatic enzyme induction.\n- Rifampicin: markedly decreases valproate exposure.\n- Other strong enzyme inducers (e.g., phenytoin, primidone): may render valproate ineffective.\n\nModerate Interactions (Monitor Closely):\n- Warfarin: valproate can increase INR, requiring closer anticoagulation monitoring.\n- Lamotrigine: combined use raises risk of severe skin reactions.\n- Topiramate: additive central nervous system depression may occur.\n- Oral contraceptives: valproate may reduce hormonal efficacy, necessitating alternative contraception.

Frequently Asked Questions

Orfiril Saft contains sodium valproate and is prescribed for several seizure types, including generalized tonic‑clonic, absence, and myoclonic seizures, as well as for Lennox‑Gastaut syndrome. It is also used off‑label for mood stabilization in bipolar disorder when indicated by a specialist.

Sodium valproate increases the level of the inhibitory neurotransmitter GABA by blocking its breakdown, and it stabilizes neuronal membranes by inhibiting voltage‑gated sodium and T‑type calcium channels. These combined actions reduce abnormal neuronal firing that leads to seizures.

The specific dose of Orfiril Saft is individualized by the prescribing clinician based on the patient’s age, weight, seizure type, and response to therapy. Dosing is adjusted gradually to achieve optimal seizure control while minimizing side effects.

Sodium valproate carries a known risk of birth defects and neurodevelopmental disorders when used during pregnancy, so it is generally avoided unless no safer alternative exists. It is excreted in breast milk, and breastfeeding decisions should be made in consultation with a healthcare professional.

To request Orfiril Saft, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other antiepileptics, sodium valproate offers broad-spectrum seizure control, covering many seizure types in a single formulation. However, it has a higher risk of hepatotoxicity and teratogenicity than some newer agents, so clinicians balance efficacy with safety based on individual patient factors.

Orfiril Saft should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and discard any solution that appears discoloured or cloudy.

Orfiril Saft is taken orally, usually measured with a calibrated dosing syringe or cup. It may be given with or without food, according to the prescriber’s instructions, and the dose is adjusted based on therapeutic response and tolerability.

The most serious risks include severe liver injury, acute pancreatitis, blood dyscrasias such as thrombocytopenia, hyperammonemic encephalopathy, and rare but life‑threatening skin reactions. Patients should be monitored regularly for signs of these conditions.

Orfiril Saft is contraindicated in patients with known hypersensitivity to sodium valproate, those with mitochondrial disorders (e.g., POLG‑related disease), and in pregnant women unless no alternative therapy is suitable. Caution is also advised for individuals with existing liver disease or significant thrombocytopenia.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sodium Valproate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT